New Market Report: Market and Product Forecasts: Non-Insulin Antidiabetics - Incretin mimetics face off in type 2 diabetes
The 2011-20 forecast period will see the loss of exclusivity for the leading non-insulin antidiabetic Actos franchise, while new launches include the first once-weekly GLP-1 agonists and the oral SGLT-2 inhibitor class, to compete in an increasingly crowded treatment algorithm in type 2 diabetes. This report was updated in May 2012 to reflect recent developments in the market.
View full press release